MedMira Inc. Logo

MedMira Inc.

MMIRF

(1.5)
Stock Price

0,05 USD

-48.93% ROA

19.92% ROE

-15.3x PER

Market Cap.

49.214.899,94 USD

-42.36% DER

0% Yield

-806.25% NPM

MedMira Inc. Stock Analysis

MedMira Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

MedMira Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (-0.86x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (-66%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

The stock's ROE falls within an average range (12.26%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

5 ROA

The stock's ROA (-42.59%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

MedMira Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

MedMira Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

MedMira Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

MedMira Inc. Revenue
Year Revenue Growth
2000 78.428
2001 373.680 79.01%
2002 114.645 -225.95%
2003 1.176.493 90.26%
2004 2.438.880 51.76%
2005 2.660.697 8.34%
2006 2.091.416 -27.22%
2007 1.705.321 -22.64%
2008 1.524.519 -11.86%
2009 1.137.645 -34.01%
2010 1.073.175 -6.01%
2011 909.869 -17.95%
2012 970.631 6.26%
2013 2.001.464 51.5%
2014 2.528.179 20.83%
2015 4.052.341 37.61%
2016 2.256.832 -79.56%
2017 747.344 -201.98%
2018 588.871 -26.91%
2019 527.445 -11.65%
2020 919.072 42.61%
2021 2.144.470 57.14%
2022 952.127 -125.23%
2023 0 0%
2023 432.529 100%
2024 326.192 -32.6%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

MedMira Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2000 761.216
2001 1.697.132 55.15%
2002 1.197.347 -41.74%
2003 819.354 -46.13%
2004 502.582 -63.03%
2005 471.732 -6.54%
2006 653.624 27.83%
2007 329.248 -98.52%
2008 333.597 1.3%
2009 317.303 -5.14%
2010 332.364 4.53%
2011 275.272 -20.74%
2012 199.022 -38.31%
2013 133.304 -49.3%
2014 294.425 54.72%
2015 604.143 51.27%
2016 2.518.546 76.01%
2017 292.299 -761.63%
2018 522.940 44.1%
2019 317.349 -64.78%
2020 199.269 -59.26%
2021 359.316 44.54%
2022 191.138 -87.99%
2023 0 0%
2023 470.683 100%
2024 796.112 40.88%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

MedMira Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 661.909
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 2.658.630 100%
2010 2.665.972 0.28%
2011 1.965.468 -35.64%
2012 2.503.025 21.48%
2013 2.101.361 -19.11%
2014 2.353.152 10.7%
2015 1.920.421 -22.53%
2016 1.472.640 -30.41%
2017 1.202.927 -22.42%
2018 1.204.322 0.12%
2019 905.901 -32.94%
2020 1.171.514 22.67%
2021 490.592 -138.8%
2022 734.833 33.24%
2023 0 0%
2023 842.612 100%
2024 810.920 -3.91%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

MedMira Inc. EBITDA
Year EBITDA Growth
2000 -2.985.315
2001 -6.332.009 52.85%
2002 -4.788.652 -32.23%
2003 -3.964.992 -20.77%
2004 -3.160.620 -25.45%
2005 -4.334.858 27.09%
2006 -5.269.139 17.73%
2007 -3.352.811 -57.16%
2008 -3.225.078 -3.96%
2009 -2.484.573 -29.8%
2010 -2.303.772 -7.85%
2011 -1.295.464 -77.83%
2012 -2.141.134 39.5%
2013 -2.410.828 11.19%
2014 -3.088.806 21.95%
2015 -2.377.397 -29.92%
2016 -4.119.071 42.28%
2017 -2.112.391 -95%
2018 -1.745.524 -21.02%
2019 -1.277.175 -36.67%
2020 -1.126.587 -13.37%
2021 185.302 707.97%
2022 -1.067.245 117.36%
2023 0 0%
2023 -1.577.239 100%
2024 -2.406.440 34.46%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

MedMira Inc. Gross Profit
Year Gross Profit Growth
2000 50.100
2001 31.437 -59.37%
2002 -333.437 109.43%
2003 426.657 178.15%
2004 1.285.355 66.81%
2005 1.086.239 -18.33%
2006 1.141.340 4.83%
2007 798.994 -42.85%
2008 538.219 -48.45%
2009 557.409 3.44%
2010 735.023 24.16%
2011 415.955 -76.71%
2012 594.236 30%
2013 630.775 5.79%
2014 774.795 18.59%
2015 1.180.366 34.36%
2016 1.019.295 -15.8%
2017 478.297 -113.11%
2018 461.111 -3.73%
2019 423.351 -8.92%
2020 572.280 26.02%
2021 1.721.742 66.76%
2022 304.027 -466.31%
2023 0 0%
2023 300.382 100%
2024 -780.448 138.49%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

MedMira Inc. Net Profit
Year Net Profit Growth
2000 -2.897.160
2001 -7.196.382 59.74%
2002 -5.658.086 -27.19%
2003 -4.615.940 -22.58%
2004 -3.992.689 -15.61%
2005 -6.106.592 34.62%
2006 -7.287.759 16.21%
2007 -6.287.523 -15.91%
2008 -7.018.042 10.41%
2009 -5.263.171 -33.34%
2010 -4.418.662 -19.11%
2011 -4.892.183 9.68%
2012 3.372.302 245.07%
2013 -402.301 938.25%
2014 -3.835.339 89.51%
2015 -3.229.565 -18.76%
2016 -5.158.401 37.39%
2017 -2.661.067 -93.85%
2018 -2.509.464 -6.04%
2019 -2.106.448 -19.13%
2020 -2.045.386 -2.99%
2021 -675.797 -202.66%
2022 -1.831.576 63.1%
2023 0 0%
2023 -2.675.658 100%
2024 -3.120.588 14.26%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

MedMira Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

MedMira Inc. Free Cashflow
Year Free Cashflow Growth
2000 -3.452.558
2001 -6.383.284 45.91%
2002 -3.668.500 -74%
2003 -3.095.381 -18.52%
2004 -3.281.120 5.66%
2005 -5.378.953 39%
2006 -7.635.704 29.56%
2007 -2.104.820 -262.77%
2008 -3.232.228 34.88%
2009 -2.022.820 -59.79%
2010 -2.692.820 24.88%
2011 -1.699.805 -58.42%
2012 -5.708 -29679.34%
2013 -2.454.823 99.77%
2014 -4.751.605 48.34%
2015 -2.346.327 -102.51%
2016 -4.119.805 43.05%
2017 -1.890.267 -117.95%
2018 -798.748 -136.65%
2019 -941.131 15.13%
2020 -417.778 -125.27%
2021 -541.186 22.8%
2022 -1.953.673 72.3%
2023 -1.269.017 -53.95%
2023 -145.205 -773.95%
2024 -950.255 84.72%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

MedMira Inc. Operating Cashflow
Year Operating Cashflow Growth
2000 -3.050.725
2001 -6.077.042 49.8%
2002 -3.656.203 -66.21%
2003 -2.986.027 -22.44%
2004 -3.080.995 3.08%
2005 -5.372.312 42.65%
2006 -7.536.696 28.72%
2007 -2.103.310 -258.33%
2008 -3.232.228 34.93%
2009 -2.022.820 -59.79%
2010 -2.637.317 23.3%
2011 -1.692.982 -55.78%
2012 0 0%
2013 -2.087.837 100%
2014 -4.655.317 55.15%
2015 -2.346.327 -98.41%
2016 -4.092.556 42.67%
2017 -1.890.267 -116.51%
2018 -795.406 -137.65%
2019 -941.131 15.48%
2020 -315.896 -197.92%
2021 -504.639 37.4%
2022 -1.883.956 73.21%
2023 -1.267.750 -48.61%
2023 -145.205 -773.08%
2024 -950.255 84.72%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

MedMira Inc. Capital Expenditure
Year Capital Expenditure Growth
2000 401.833
2001 306.242 -31.21%
2002 12.297 -2390.38%
2003 109.354 88.75%
2004 200.125 45.36%
2005 6.641 -2913.48%
2006 99.008 93.29%
2007 1.510 -6456.82%
2008 0 0%
2009 0 0%
2010 55.503 100%
2011 6.823 -713.47%
2012 5.708 -19.53%
2013 366.986 98.44%
2014 96.288 -281.13%
2015 0 0%
2016 27.249 100%
2017 0 0%
2018 3.342 100%
2019 0 0%
2020 101.882 100%
2021 36.547 -178.77%
2022 69.717 47.58%
2023 1.267 -5402.53%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

MedMira Inc. Equity
Year Equity Growth
2000 -3.278.170
2001 -6.006.841 45.43%
2002 -7.447.265 19.34%
2003 -2.186.516 -240.6%
2004 -5.873.770 62.77%
2005 -9.804.644 40.09%
2006 -8.045.654 -21.86%
2007 -12.778.114 37.04%
2008 -13.940.519 8.34%
2009 -15.996.844 12.85%
2010 -16.664.018 4%
2011 -19.113.699 12.82%
2012 -8.708.299 -119.49%
2013 -9.110.600 4.42%
2014 -6.690.067 -36.18%
2015 -7.704.367 13.17%
2016 -7.662.159 -0.55%
2017 -8.984.541 14.72%
2018 -11.398.016 21.17%
2019 -13.516.964 15.68%
2020 -15.562.350 13.14%
2021 -15.723.898 1.03%
2022 -12.355.997 -27.26%
2023 -15.031.655 17.8%
2023 -13.478.954 -11.52%
2024 -16.861.581 20.06%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

MedMira Inc. Assets
Year Assets Growth
2000 3.615.563
2001 3.027.814 -19.41%
2002 3.362.470 9.95%
2003 2.360.613 -42.44%
2004 1.693.535 -39.39%
2005 1.428.144 -18.58%
2006 4.007.947 64.37%
2007 2.864.036 -39.94%
2008 833.187 -243.74%
2009 523.414 -59.18%
2010 568.178 7.88%
2011 1.492.123 61.92%
2012 2.970.239 49.76%
2013 1.166.845 -154.55%
2014 1.841.927 36.65%
2015 1.783.652 -3.27%
2016 869.905 -105.04%
2017 673.705 -29.12%
2018 300.912 -123.89%
2019 252.518 -19.16%
2020 3.396.075 92.56%
2021 3.890.072 12.7%
2022 3.829.573 -1.58%
2023 3.651.802 -4.87%
2023 3.724.057 1.94%
2024 6.364.299 41.49%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

MedMira Inc. Liabilities
Year Liabilities Growth
2000 6.893.733
2001 9.034.655 23.7%
2002 10.809.735 16.42%
2003 4.547.129 -137.73%
2004 7.567.305 39.91%
2005 11.232.788 32.63%
2006 12.053.601 6.81%
2007 15.642.150 22.94%
2008 14.773.706 -5.88%
2009 16.520.258 10.57%
2010 17.232.196 4.13%
2011 20.605.822 16.37%
2012 11.678.538 -76.44%
2013 10.277.445 -13.63%
2014 8.531.994 -20.46%
2015 9.488.019 10.08%
2016 8.532.064 -11.2%
2017 9.658.246 11.66%
2018 11.698.928 17.44%
2019 13.769.482 15.04%
2020 18.958.425 27.37%
2021 19.613.970 3.34%
2022 16.185.570 -21.18%
2023 18.683.457 13.37%
2023 17.203.011 -8.61%
2024 23.225.880 25.93%

MedMira Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-15.3x
Price To Sales Ratio
128.39x
POCF Ratio
-19.27
PFCF Ratio
-19.9
Price to Book Ratio
-2.83
EV to Sales
143.89
EV Over EBITDA
-27.22
EV to Operating CashFlow
-22.31
EV to FreeCashFlow
-22.3
Earnings Yield
-0.07
FreeCashFlow Yield
-0.05
Market Cap
0,05 Bil.
Enterprise Value
0,06 Bil.
Graham Number
0.05
Graham NetNet
-0.03

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.79
ROE
0.2
Return On Assets
-0.55
Return On Capital Employed
0.17
Net Income per EBT
1
EBT Per Ebit
1.28
Ebit per Revenue
-6.3
Effective Tax Rate
-0.18

Margins

Sales, General, & Administrative to Revenue
2.45
Research & Developement to Revenue
1.29
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.45
Operating Profit Margin
-6.3
Pretax Profit Margin
-8.06
Net Profit Margin
-8.06

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0.01
Return on Invested Capital
0.27
Return on Tangible Assets
-0.49
Days Sales Outstanding
1285.3
Days Payables Outstanding
1659.37
Days of Inventory on Hand
124.56
Receivables Turnover
0.28
Payables Turnover
0.22
Inventory Turnover
2.93
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,02
Tangible Book Value per Share
-0.02
Shareholders Equity per Share
-0.02
Interest Debt per Share
0.01
Debt to Equity
-0.42
Debt to Assets
1.12
Net Debt to EBITDA
-2.93
Current Ratio
0.22
Tangible Asset Value
-0,02 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
-14290427
Working Capital
-0,02 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
209736
Debt to Market Cap
0.15

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

MedMira Inc. Dividends
Year Dividends Growth

MedMira Inc. Profile

About MedMira Inc.

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. In addition, the company offers VYRA CoV2 that detects antigens specific for the nucleocapsid region of SARS-CoV-2; VYRA CoV2Flu, a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2, and Influenza A and Influenza B; and REVEALCOVID-19, an antibody test. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.

CEO
Mr. Hermes Chan
Employee
0
Address
155 Chain Lake Drive
Halifax, B3S 1B3

MedMira Inc. Executives & BODs

MedMira Inc. Executives & BODs
# Name Age
1 Mr. Hermes Chan
Co-Founder, Chief Executive Officer, President & Director
70
2 Mr. Markus M. Meile
Chief Financial Officer
70
3 Dr. Sam Ratnam
Director of Scientific & Regulatory Affairs
70
4 Stewart McKelvey
Legal Counsel
70
5 Dr. Kevin D. Jones
Head of Commercialization and Senior Director of Sales & Marketing
70

MedMira Inc. Competitors